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The lipopolysaccharide of certain strains of Helico-
bacter pylori was recently shown to contain the Lewis X
(Lex) trisaccharide (Galb-1,4-(Fuca(1,3))-GlcNAc). Lex is
an oncofetal antigen which appears on human gastric
epithelium, and its mimicry by carbohydrate structures
on the surface of H. pylori may play an important part in
the interaction of this pathogen with its host. Potential
roles for bacterial Lex in mucosal adhesion, immune
evasion, and autoantibody induction have been pro-
posed (Moran, A. P., Prendergast, M. M., and Appelmelk,
B. J. (1996) FEMS Immunol. Med. Microbiol. 16, 105–115).
In mammals, the final step of Lex biosynthesis is the
a(1,3)-fucosylation of GlcNAc in a terminal Galb(134)-
GlcNAc unit, and a corresponding GDP-fucose:N-acetyl-
glucosaminyl a(1,3) fucosyltransferase (a(1,3)-Fuc-T) ac-
tivity was recently discovered in H. pylori extracts. We
used part of a human a(1,3)-Fuc-T amino acid sequence
to search an H. pylori genomic data base for related
sequences. Using a probe based upon weakly matching
data base sequences, we retrieved clones from a plasmid
library of H. pylori DNA. DNA sequence analysis of the
library clones revealed a gene which we have named
fucT, encoding a protein with localized homology to the
human a(1,3)-Fuc-Ts. We have demonstrated that fucT
encodes an active Fuc-T enzyme by expressing the gene
in Escherichia coli. The recombinant enzyme shows a
strong preference for type 2 (e.g. LacNAc) over type 1
(e.g. lacto-N-biose) acceptors in vitro. Certain residues
in a short segment of the H. pylori protein are com-
pletely conserved throughout the a(1,3)-Fuc-T family,
defining an a(1,3)-Fuc-T motif which may be of use in
identifying new fucosyltransferase genes.
The Gram-negative bacterium Helicobacter pylori is a major
cause of chronic gastritis and peptic and duodenal ulcers (1–5).
It has also been implicated in gastric adenocarcinoma (6–9)
and gastric lymphoma (10), leading to its classification as a
type I human carcinogen (11). H. pylori is a chronic pathogen,
and the means by which this organism is able to persist in the
stomach and resist or evade destruction by the immune system
is central to its involvement in disease. Some aspects of the
host-pathogen interaction have been resolved, including the
involvement of the Lewis b (Leb)1 epitope on epithelial cells in
attachment of H. pylori (12), and characterization of a bacterial
cytotoxin responsible for gastric epithelial damage (for a review
see Ref. 13), but clearly much remains to be discovered.
Recent structural analysis of H. pylori lipopolysaccharides
revealed that the O antigen contains fucosylated carbohydrate
structures identical to the mammalian Lewis X (Lex) and Lewis
Y (Ley) epitopes (14–17). It was further established that the
bacterium contains endogenous galactosyltransferase (Gal-T)
and fucosyltransferase (Fuc-T) activities necessary for biosyn-
thesis of these structures (18) suggesting that they are synthe-
sized de novo by H. pylori rather than scavenged from the
surface of mammalian cells. Lex is an oncofetal antigen (19, 20)
also expressed on adult human gastric mucosa (21), and its
presence on H. pylori lipopolysaccharides may play a role in
survival and pathogenesis. H. pylori infection is known to in-
duce antibodies that cross-react with human gastric mucosa
(22). In a recent report, Appelmelk et al. (23) demonstrated that
the targets of this autoimmune response include Lex and/or Ley
epitopes and provided evidence that anti-Lex/y antibodies may
be involved in H. pylori-associated gastritis. Interestingly, mo-
lecular mimicry of Lex is also thought to be responsible for
autoantibody production by Schistosoma mansoni (24, 25). In
addition, surface carbohydrate antigens containing Lex struc-
tures may play a part in the immunopathology of H. pylori
infection by promoting Th-1 to Th-2 switching as has been
reported in schistosomal infections (26). Two recent reports (27,
28) that over 85% of H. pylori isolates from geographically
widespread locations express Lex and/or Ley antigens would
also seem to imply selective pressure for maintenance of these
structures, given the considerable structural variability often
shown by lipopolysaccharides from Gram-negative bacteria.
In mammals, the defining step of Lex biosynthesis is fucosyl-
ation of a type 2 core structure (Galb134GlcNAc). This reac-
tion is catalyzed in humans by one or more members of a family
of a(1,3)-fucosyltransferases which employ GDP-fucose as an
activated sugar donor (29–38). Fuc-T and Gal-T activities have
been detected in H. pylori extracts (18), but although the order
of sugar transfer appears to follow the same course as in
mammalian systems, with galactosylation preceding fucosyla-
tion, little is known about the bacterial Fuc-T and how it is
related to the mammalian transferases. If, as evidence is be-* The costs of publication of this article were defrayed in part by the
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ginning to suggest, cell-surface Lex/y epitopes play an impor-
tant role in H. pylori persistence and pathogenesis (23, 39), the
a(1,3)-Fuc-T may offer a nonbactericidal therapeutic target for
eradication of H. pylori without otherwise disturbing the bal-
ance of gut fauna.
Five members of the human a(1,3)-Fuc-T gene family have
been cloned (Fuc-TIII–VII) (29–38). Homologs of some of these
genes have also been cloned from mouse (40–42), rat (43), and
cow (44) cDNA. The remarkable degree of sequence conserva-
tion between mammalian a(1,3)-Fuc-Ts and the recently cloned
chicken a(1,3)-fucosyltransferase (CFT1) (45) suggests that
other nonmammalian a(1,3)-Fuc-Ts may also show significant
homology to the known members of this enzyme family. We
describe here the identification and cloning of a gene from H.
pylori, fucT, which encodes an active Fuc-T with localized se-
quence similarity to the a(1,3)-Fuc-Ts.
EXPERIMENTAL PROCEDURES
Materials—GDP-fucose and N-acetyllactosamine were from Sigma.
AG 1-X8 mixed bed resin was from Bio-Rad. GDP-[3H]fucose (2.22
TBq/mmol) was obtained from Amersham. Oligosaccharides were ob-
tained from Dextra and Oxford Glycosystems. Xanthomonas manihotis
a(1,2)- and a(1,3/4)-fucosidases and Streptomyces plicatus N-acetyl-b-
hexosaminidase were from New England Biolabs. Bovine testis b-ga-
lactosidase was from Bo¨ehringer Mannheim. Bacteroides fragilis endo-
b-galactosidase was supplied by Oxford Glycosystems. Neutropak NH2
HPLC columns (5 mm, 150 3 4.6 mm) were from Capital Analytical. H.
pylori NCTC 11637 was obtained from the National Collection of Type
Cultures (NCTC). Buffer and media components were obtained from
Sigma, Difco, and Life Technologies, Inc. All chemicals were of the
highest available purity. Chemiluminescent detection film was from
Kodak.
Hybridization to the H. pylori Plasmid Library—A 363-bp sequence
fragment from the H. pylori genomic data base containing the Fuc-T
homology region was amplified from H. pylori NCTC 11637 genomic
DNA by PCR using the primers HPFT1 (59-CTT TGA AAA GAG GGT
TTG CCA) and HPFT2 (59-CAA GTA TCT CAC GTA ATC AAT). Am-
plified product was purified using the QiaQuick PCR purification sys-
tem (Qiagen) following the manufacturer’s instructions. Approximately
0.5 mg of the purified fragment was used to prepare DIG-labeled probe
using the DIG Hi-prime labeling kit (Boehringer Mannheim). Probe
was used without further purification.
Nylon membranes carrying plasmid DNA from an H. pylori plasmid
library in high density gridded format were kindly supplied by Dr C. L.
Clayton (Genomics Unit, GlaxoWellcome). Membranes were prehybrid-
ized for 4 h at 42 °C in 20 ml of 50% formamide (v/v), 1% SDS (w/v), 7.5%
(w/v) dextran sulfate, 1 M sodium chloride, 1.5 3 Denhardt’s solution
(46), 1.7 mM sodium pyrophosphate, 37.5 mM TriszHCl, pH 7.5, contain-
ing 0.1 mg/ml denatured salmon sperm DNA. Probe was denatured by
boiling for 5 min and added to the prehybridization buffer; hybridiza-
tions were carried out overnight at 42 °C. Membranes were washed
twice for 30 min in 2 3 SSC, 0.1% (w/v) SDS, room temperature; 1 3
SSC, 0.1% (w/v) SDS, 45 °C; 0.1 3 SSC, 0.1% (w/v) SDS, 68 °C. Detec-
tion was performed using the Boehringer Mannheim chemiluminescent
DIG detection system with CSPD luminescent substrate. Membranes
were exposed to film for 5–120 min at room temperature.
Library Clone Retrieval and Sequence Analysis—Clones which hy-
bridized strongly to the probe were retrieved from 384-well library
storage microtiter plates (stored at 280 °C) and grown overnight in 2 ml
of L broth containing 100 mg/ml ampicillin. DNA was prepared by the
rapid alkaline lysis method (46). Larger quantities of plasmid DNA
were obtained from 1–200-ml cultures using the Qiagen plasmid (maxi)
system. DNA sequencing reactions performed using AmpliTaq FS with
dye terminators (Perkin-Elmer) and run on an Applied Biosystems ABI
373 automated sequencer. Sequence analysis was performed using
GCG 8.1 (47) and BLAST (48) software. Sequence alignments were
created with Pileup (part of the GCG package) with a gap penalty of 5.0
and gap extension penalty of 0.5.
Subcloning of fucT into an E. coli Expression Vector—A 1.4-kb DNA
fragment containing the fucT gene was amplified from H. pylori
NCTC11637 genomic DNA by PCR using the primers HPFT3 (59-GAG
TGT CTA ATG GGA TCC TTA TTT TTT AAC CCA CCT) and HPFT5
(59-TAG CCC TAA TCA AGC CTT TG). PCR product was purified using
the QiaQuick PCR purification system (Qiagen), ligated to the A/T
cloning vector pCRTMII (Invitrogen) and introduced into Escherichia
coli XL-1 Blue (Stratagene) by electroporation. Recombinant (white)
clones were mapped with BssHII to identify plasmids containing the
cloned fragment in the desired orientation (direction of transcription of
fucT in the same direction as lacZ). A 1.4-kb fragment containing the
fucT gene was excised from a suitable clone with BamHI and ligated to
pET-11a vector DNA (Novagen) which had been linearized with BamHI
and dephosphorylated using shrimp alkaline phosphatase (Amer-
sham, Little Chalfont, UK). Ligated DNA was introduced into E. coli
BL21(DE3), and transformants were selected on L agar containing
ampicillin (100 mg/ml). Recombinant clones were identified by restric-
tion mapping with BssHII.
Preparation of Cell Extracts—Recombinant clones were grown over-
night at 37 °C from single colony inocula in 5 ml of L broth containing
100 mg/ml ampicillin. 20 ml of fresh L broth was inoculated with 200 ml
of the overnight culture and incubated at 37 °C. E. coli XL-1 Blue
containing library plasmids were grown for 5–8 h prior to harvesting. E.
coli BL21(DE3) containing the expression plasmid pHPFT was incu-
bated until an A600 of 0.4–0.6 was attained. Isopropyl-1-thio-b-D-galac-
topyranoside was added to a final concentration of 0.5 mM, and incuba-
tion continued for an additional 3 h. Bacteria were harvested by
centrifugation (4000 3 g, 15 min, 4 °C) and washed in phosphate-
buffered saline. Pelleted bacteria were resuspended in 0.5 ml of chilled
solubilization buffer (0.1% (w/v) Triton X-100, 0.1 M NaCl, 25% (w/v)
glycerol, 0.1 M NaCl, 2 mM dithiothreitol, 50 mM Tris-HCl, pH 7.0) and
sonicated on ice for 4 3 15 s bursts (MSE Soniprep 150), with a 60-s
cooling period on ice between bursts. Sonicate was cleared by centrifu-
gation (20,000 3 g, 30 min, 4 °C) and stored at 280 °C.
Fucosyltransferase Assays—Fucosyltransferase activity was meas-
ured by a modification (49) of the method of Prieels et al. (50). Briefly,
12.5 ml of cell extract was incubated with 20 mM GDP-fucose, 100,000
cpm of GDP-[3H]fucose, 5 mM acceptor, 5 mM MnCl2, 1 mM ATP, buff-
ered to pH 7.2 with 50 mM HEPES-NaOH in a total volume of 50 ml for
1 h at 37 °C. Sensitivity of the H. pylori enzyme to the inhibitor N-
ethylmaleimide (NEM) was assessed by including NEM at final concen-
trations of up to 15 mM in Fuc-T assay reactions. Reactions were
stopped by addition of 1 ml of mixed bed resin slurry (AG 1-X8 (Cl2
form) 1:4 (w/v) in water), vortexed briefly, and centrifuged for 5 min at
20,000 3 g at room temperature. Radioactivity in 600 ml of supernatant
was measured by scintillation counting. Allowance was made for non-
specific breakdown of GDP-fucose and fucose transfer to endogenous
acceptors by performing control reactions in the absence of acceptor.
Assay reactions were performed in duplicate. Km for the acceptor N-
acetyllactosamine (LacNAc) was determined by measuring reaction
rates with 0–100 mM LacNAc and 200 mM GDP-fucose, while the donor
Km was obtained using 0–100 mM GDP-fucose and 5 mM LacNAc.
Purification of Fucosylated Oligosaccharides Generated using H. py-
lori Fuc-T—0.5 ml of H. pylori Fuc-T (approximately 0.2 milliunit) was
incubated with 5 mM acceptor (LacNAc or LNT), 3 mM GDP-fucose,
800,000 cpm of GDP-[3H] fucose, 0.1% (w/v) BSA, 2 ml (2 units) of
shrimp alkaline phosphatase, 5 mM MnCl2, buffered to pH 7.2 with 50
mM HEPES-NaOH in 1 ml total volume for 40 h at 37 °C. Incubation
mixtures were passed through a 2.5-ml Dowex AG 1-X8 ion exchange
column, washed through with 7.5 ml of water. Column eluant and
washings were pooled, evaporated to dryness, and redissolved in 0.5 ml
of water. Samples from the Dowex column were applied to a Bio-Gel P2
gel filtration column (20 3 1 cm) eluted with water at 20 ml/h. 1-ml
fractions were collected, and 5-ml aliquots were removed for liquid
scintillation counting. Radioactive fractions were pooled and lyophi-
lized, keeping discrete eluant peaks separate. To remove residual Tri-
ton X-100, products were dissolved in 500 ml of water and applied to
disposable 100-mg Amprep C18 reverse phase columns (Amersham),
washed through with 3 ml of water. Pooled eluant and washings were
lyophilized and redissolved in 100 ml of water. Finally, fucosylated
products were purified by HPLC on a Neutropak NH2 column in water/
acetonitrile (25:75 by volume for products derived from LacNAc, 30:70
by volume for those produced from LNT). 0.5-ml fractions were col-
lected, and radioactive fractions were pooled, lyophilized, and redis-
solved in 100 ml of water.
Glycosidase Treatment of Fucosylated Oligosaccharides—20 ml of the
purified LacNAc-derived product was incubated overnight at 37 °C
with 3 units (units as defined by the supplier) of a(1,3/4)- or a(1,2)-
fucosidase from X. manihotis in 30 ml of 50 mM sodium citrate, pH 6.0,
containing 100 mg/ml BSA. 20 ml of the LNT-derived product was
incubated overnight at 37 °C with 6.25 milliunits of B. fragilis endo-
b-galactosidase in 50 ml of 50 mM sodium acetate, pH 5.7, containing
250 mg/ml BSA; 10 milliunits of bovine testis b-galactosidase in 50 ml of
50 mM sodium citrate, pH 4.5; or 10 milliunits of bovine testis b-galac-
tosidase and 10 milliunits of S. plicatus N-acetyl-b-hexosaminidase
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in 50 ml of 50 mM sodium citrate, pH 4.5.
Glycosidase reaction products were analyzed by HPLC on the Neu-
tropak NH2 column in water/acetonitrile (25:75 by volume for products
derived from LacNAc, 30:70 by volume for those generated from LNT).
Elution profiles were generated by collecting 0.5-ml fractions for scin-
tillation counting. Retention times for unlabeled oligosaccharide stand-
ards (LacNAc and for products derived from LacNAc using H. pylori
Fuc-T, LNT, LacNAc, and Lex for those generated using LNT as accep-
tor) under corresponding chromatographic conditions were determined
by monitoring absorbance at 205 nm.
RESULTS
Identification of a Fucosyltransferase Gene in H. pylori
NCTC 11637—Human a(1,3)-fucosyltransferases (Fuc-TIII–
VII) show a high degree of sequence similarity at the amino
acid level. To identify H. pylori sequences with homology to
the human fucosyltransferase enzymes, we performed a
TBLASTN2 search of a GlaxoWellcome H. pylori genomic data
set with part of the catalytic domain (residues 152–303) of
human Fuc-TVI, a strongly conserved region among the human
a(1,3)-Fuc-T family. A number of H. pylori sequence fragments
showed weak similarity to the query (maximum BLAST score
0.0025), with matches localized to a short region in each case
(17 identities in 30 amino acids). Codon usage plots indicated
that this reading frame was likely to be protein coding (data not
shown). Closer examination of the sequence alignments re-
vealed that several of the matching residues from the H. pylori
sequence are conserved across all five human a(1,3)-Fuc-Ts,
suggesting that the data base sequence fragments may be part
of a related H. pylori gene. Since both a(1,3)-Fuc-T and b(1,4)-
Gal-T Lex forming activities have been reported in H. pylori (18),
we carried out a similar search with part of the catalytic domain
of human b(1,4-Gal-T), but found no matching sequences.
Using primers derived from one of the matching data base
sequences, we amplified a short (approximately 400 bp) DNA
fragment from H. pylori NCTC 11637 genomic DNA which was
subsequently labeled with digoxigenin and used to identify
hybridizing clones in a plasmid library of DNA from the same
organism. Seven strongly hybridizing clones were retrieved
from the library for DNA sequence analysis, which revealed
considerable overlap between the cloned sequences in all seven
plasmids. DNA sequencing of all seven clones in both strands
yielded a total of approximately 2.7 kb of contiguous sequence
(Fig. 1A). The probe sequence occurs within the only complete
open reading frame in the sequence (designated fucT), span-
ning 1002 bp and coding for a predicted 333-amino acid
polypeptide with localized sequence homology to the human
a(1,3)-Fuc-Ts. A partial open reading frame occurs approxi-
mately 500 bp upstream of the fucT gene, running in the same
direction. The predicted translation of this part of the H. pylori
sequence shows homology to phosphoserine phosphatase (serB)
genes from Gram-negative bacteria, with greatest similarity to
the Haemophilus influenzae sequence (37% identity, 65 match-
ing residues over 173 amino acids).
Primary Structure of H. pylori fucT—The nucleotide se-
quence and predicted translation of H. pylori fucT are shown in
Fig. 1. The GC content of the gene (36%) is typical for H. pylori
coding sequences (3). The predicted amino acid sequence con-
tains no recognizable signal peptide or transmembrane do-
main, a Kyte-Doolittle plot revealing that hydrophobic regions
of the sequence are small and infrequent (Fig. 1B). A repetitive
element occupies 49 amino acids of the C-terminal part of the
protein. The repeat unit is imperfect, but leucine appears con-
sistently at 7-amino acid intervals in a pattern reminiscent of
the eukaryotic leucine zipper motif.
The similarity between the fucT gene product and other
a(1,3)-Fuc-T is weak outside the short region originally identi-
fied by the data base search, spanning residues 101 to 129 of
the H. pylori protein. Within this part of the sequence, how-
ever, 10 residues are completely conserved in all five human
a(1,3)-Fuc-Ts and also appear unchanged in bovine, murine,
and avian a(1,3)-Fuc-T enzymes (Fig. 2). In addition, there are
a number of partially conserved positions (occupied by one of
two amino acids). Outside this region, similarity to other mem-
bers of the a(1,3)-Fuc-T family diminishes very quickly, al-
though a number of isolated conserved residues can be identified.
No significant similarity to any enzyme class other than the
a(1,3)-Fuc-T family could be found for the H. pylori sequence.
Given the reported occurrence of Lex structures on the H.
pylori O antigen and detection by others (18) and ourselves3 of
corresponding a(1,3)-Fuc-T activity in cell extracts from this
bacterium, we took the exclusive, albeit localized, similarity
between the deduced amino acid sequence of H. pylori fucT and
a(1,3)-Fuc-T enzymes as an indication that it may encode an H.
pylori fucosyltransferase enzyme.
Fucosyltransferase Activity—We assayed cell lysates from the
clones retrieved from the H. pylori plasmid library for a(1,3)-
Fuc-T activity using N-acetyllactosamine (Galb134GlcNAc) as
an acceptor. All seven of the library clones tested showed meas-
urable Fuc-T activity, while neither control clones containing
pUC18 nor untransformed E. coli possessed any activity (Table
I), demonstrating that cloned H. pylori sequences contained in
the library plasmids encode an active Fuc-T.
Cloning H. pylori fucT into an E. coli Expression Vector—The
H. pylori library plasmids contain stretches of flanking se-
quence on either side of fucT. To exclude the possibility that
coding sequences outside the identified fucT gene were respon-
sible for the observed Fuc-T activity, and in an effort to in-
crease levels of recombinant fucosyltransferase activity, we
subcloned H. pylori fucT into the E. coli expression vector
pET-11a. The resulting plasmid, pHPFT, contains fucT as the
sole H. pylori-derived coding sequence under control of the
T7lac promoter. E. coli BL21(DE3) containing pHPFT pro-
duced Fuc-T activity when induced with isopropyl-1-thio-b-D-
galactopyranoside, extracts typically showing a specific activity
of 100–200 pmol/min/mg with N-acetyllactosamine as acceptor.
Some activity could also be detected in uninduced samples
(10–20% of induced levels), presumably as a result of “leaky”
promoter repression. Maximal activity levels produced from
pHPFT were not, as we had hoped, substantially higher than
those in the library clones, nor was a highly expressed protein
of the expected molecular mass (approximately 40 kDa) appar-
ent from SDS-polyacrylamide gel electrophoresis analysis of
uncleared cell extracts (data not shown). The limited Fuc-T
activity produced by pHPFT thus appears to result from lim-
ited expression rather than accumulation of highly expressed
but insoluble and inactive recombinant protein.
Acceptor Specificity of H. pylori Fuc-T—We measured the
activity of recombinant H. pylori FucT with a panel of oligosac-
charide acceptors, as shown in Table II. The enzyme strongly
preferred type 2 (Galb134GlcNAc) structures over type 1
(Galb133GlcNAc) acceptors. The type 2 tetrasaccharide (9)
was a better acceptor than LacNAc (1) suggesting that H. pylori
FucT may prefer to fucosylate b-configured GlcNAc. Similar
preferences have been reported for human Fuc-TIV and to a
lesser extent for Fuc-TV with these two acceptors (51). With
sialylated LacNAc acceptors the H. pylori FucT most closely
resembled human Fuc-Ts V and VII in that 39-sialyl-LacNAc
(6) was a substrate, while 69-sialyl-LacNAc (7) was not (51, 52).
2 TBLASTN compares a peptide query sequence with the translation
in all six frames of a nucleotide data base. 3 V. A. Kelly, C. J. Britten, and S. L. Martin, unpublished observation.
Helicobacter pylori Fucosyltransferase 21351
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
No activity was observed with the type 1 disaccharide lacto-N-
biose (2), although lacto-N-tetraose (LNT) (10) was an efficient
acceptor. Fucosylation of the terminal galactose of LNT in the
2-position (11) or GlcNAc in the 4-position (12) significantly
reduced incorporation rates, while fucosylation on both GlcNAc
and glucose (15) abolished fucose incorporation altogether.
This suggests that H. pylori FucT may may be capable of
fucosylating predominantly the glucose residue of LNT-based
acceptors, as has been demonstrated for Fuc-TV (51). 69-Sialy-
lation of GlcNAc also blocked fucosylation of type 2 structures
with the recombinant H. pylori enzyme (18) whereas 39-sialy-
lation of the terminal galactose residue (17) caused only a
minor reduction in relative activity. Unlike Fuc-TV (but like
Fuc-TVI and Fuc-TVII), however, the H. pylori Fuc-T showed
no activity toward 29-fucosyllactose (5), implying that in the
synthesis of Ley by H. pylori a2-fucosylation of Gal may occur
after a3-fucosylation of GlcNAc. Taken together, these results
suggest that the Helicobacter enzyme has little a(1,2)- or a(1,4)-
Fuc-T activity, but efficiently a(1,3)-fucosylates neutral and
a(2,3)-sialylated type 2 acceptors. To further define the cata-
lytic properties of H. pylori Fuc-T, Km values were determined
for LacNAc (0.5 mM) and GDP-fucose (9 mM). Sensitivity to the
FIG. 1. A, nucleotide sequence and pre-
dicted translation of H. pylori fucT. An
upstream partial open reading frame
with homology to H. influenzae and E. coli
serB genes is underlined. B, Kyte-
Doolittle hydrophobicity plot of H. pylori
fucT. Hydrophobic domains are plotted
above the axis, hydrophilic domains
below.
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inhibitor NEM was measured by performing assays in the
presence of NEM at concentrations up to 15 mM. The enzyme
showed very limited NEM sensitivity, with Fuc-T activity re-
duced by only 34% in the presence of 15 mM NEM. For com-
parison, FucT-III (expressed in COS cells) is inhibited approx-
imately 85% at the same NEM concentration, while extracts
from Schistosoma mansoni and COS cells expressing Fuc-TIV
retain about 50% of their Fuc-T activity (53).
Analysis of Fucosylated Products Generated by H. pylori Fuc-
T—Some of the inferences drawn from the acceptor preferences
of H. pylori Fuc-T were investigated further by examining the
sensitivity of fucosylated products to glycosidase treatment.
Radiolabeled oligosaccharide products were generated by incu-
bating the acceptors LacNAc and LNT with H. pylori Fuc-T in
the presence of GDP-[3H]fucose. Following removal of excess
sugar nucleotide, free fucose and residual Triton X-100 from
the reaction mixture by successive ion exchange, size exclusion,
and reverse phase chromatographic steps, oligosaccharide
products were purified by HPLC on a Neutropak NH2 column.
Incubation of LacNAc with H. pylori Fuc-T yielded a single
radiolabeled product with a retention time on HPLC corre-
sponding to that of Lex (Fig. 3A). The product was unaffected by
treatment with a selective a(1,2)-fucosidase, while treatment
with a(1,3/4)-fucosidase resulted in complete conversion to a
new product which eluted from the Neutropak NH2 column
more rapidly than LacNAc. These observations support the
conclusion that the major fucosylated product generated by H.
pylori Fuc-T with LacNAc as acceptor is the Lex trisaccharide.
Accordingly, the product is resistant to a(1,2)-fucosidase, but
sensitive to a(1,3/4)-fucosidase, which liberates fucose as the
sole radiolabeled product.
To investigate the fucosylation of the type 1 acceptor LNT
(10) by H. pylori Fuc-T, labeled product was treated with endo-
b-galactosidase. The action of this glycosidase is inhibited by
fucosylation of residues flanking the b-galactoside linkage (54,
55) and thus if, as substrate preferences seem to suggest, H.
pylori Fuc-T fucosylates the glucose residue of LNT, the prod-
uct should be resistant to endo-b-galactosidase cleavage. Since
endo-b-galactosidase activity may also be hampered by fucosyl-
ation at more distant sites (for example, on GlcNAc or the distal
Gal residue of LNT) (55), the product was also treated with
bovine testis b-galactosidase, alone or in combination with
b-N-acetylhexosaminidase, to examine this possibility. Analy-
sis of the labeled oligosaccharides produced by glycosidase di-
gestion of H. pylori Fuc-T-generated fucosyl-LNT is shown in
Fig. 3B. As expected, endo-b-galactosidase had no effect on the
FIG. 2. A, sequence alignment of H. py-
lori Fuc-T with other Fuc-Ts. Aligned se-
quences are: human Fuc-TIII, -IV, and
-VII (FT-III, -IV, -VII, respectively), mu-
rine Fuc-TVII (Mu-FTVII), chick Fuc-T
(CFT1), a cosmid-derived C. elegans se-
quence (C. elegans),4 and a translation of
the H. pylori fucT gene (H. pylori). Se-
quences are ordered according to similar-
ity. Transmembrane domains are shaded.
The position of Cys143 in Fuc-TIII, impli-
cated in inhibition by NEM, is arrowed. A
repetitive element in the H. pylori se-
quence is underlined and in bold. Com-
pletely conserved residues are indicated
below the alignment. A region of strong,
localized homology is boxed. B, a(1,3)-
Fuc-T motif. All known a(1,3)-Fuc-Ts con-
tain this short peptide motif. Fully con-
served residues are indicated in one-letter
code, two letters arranged vertically indi-
cate that either of the corresponding
amino acids may occupy this position. As
shown here, the motif represents a mini-
mal consensus and those positions which
may be occupied by more than two differ-
ent amino acids, or by two unrelated res-
idues, are indicated as unconserved posi-
tions, designated X. The asterisked
position is occupied by Ile or Val in all
a(1,3)-Fuc-Ts except in the recently
cloned rat gene, where it is occupied by
Asn.
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fucosylated oligosaccharide, while LNT itself was readily
cleaved under similar conditions (data not shown). Digestion
with bovine testis exo-b-galactosidase resulted in substantial
(.50%) conversion to a product with a retention time close to
that of LNT. This indicates that the distal Gal residue of the
major product is not fucosylated, as this would otherwise block
exo-b-galactosidase action. Combined treatment with b-galac-
tosidase and N-acetyl-b-hexosaminidase yielded a more rapidly
eluting product, consistent with removal of distal Gal and
GlcNAc residues to leave a fucose-containing trisaccharide.
Further b-galactosidase action is presumably blocked by fucose
branching at the Glc residue of the remaining galactoside.
These findings suggest that H. pylori Fuc-T fucosylates LNT
predominantly at the glucose residue. Resistance of part of the
product material to bovine testis b-galactosidase may reflect
some degree of a(1,2)- or a(1,4)-fucosylation, although the sub-
strate preferences of this Fuc-T indicate that incomplete galac-
tosidase digestion is perhaps a more likely explanation.
DISCUSSION
By searching an H. pylori genomic data set with part of the
catalytic domain sequence of a human a(1,3)-Fuc-T and se-
quencing corresponding clones from a plasmid library of H.
pylori DNA we were able to identify a gene (fucT) with highly
localized similarity to known a(1,3)-Fuc-T enzymes. Cell ex-
tracts from library clones containing the H. pylori gene pos-
sessed Fuc-T activity, and by subcloning fucT into an E. coli
expression vector we were able to confirm that it encodes an
active a(1,3)-Fuc-T. H. pylori fucT is the first Fuc-T gene to be
cloned from an invertebrate, although enzyme activity has
been detected in the freshwater snail Lymnea stagnalis (56)
and in the parasite S. mansoni (53).
Sequence similarity between the mammalian Fuc-Ts and
chick fucosyltransferase (CFT1) provided evidence for evolu-
tionary conservation of a(1,3)-Fuc-T sequences (45). Conserva-
tion between H. pylori FucT and the mammalian enzymes,
although limited and highly localized, suggests that aspects of
the a(1,3)-Fuc-T sequence have survived unchanged through
evolution from bacteria to higher mammals and man. The lack
of overall sequence similarity to human a(1,3)-Fuc-Ts would
seem to preclude the idea that H. pylori acquired the Fuc-T
gene from a mammalian source. The base composition of the
gene (35% GC) is also much closer to the average for H. pylori
(36%) than to mammalian and avian a(1,3)-Fuc-T genes, which
are typically GC-rich (e.g. CFT-1, 69% GC).
Unlike eukaryotic Fuc-Ts which have a hydrophobic trans-
membrane domain near their N terminus and share a common
type II membrane protein topology, the H. pylori enzyme con-
FIG. 3. A, glycosidase/HPLC analysis of fucosylated LacNAc gener-
ated by H. pylori Fuc-T. Purified labeled product was analyzed by
chromatography on a Neutropak NH2 column under isocratic conditions
using water/acetonitrile (25:75 by volume) following no treatment (l),
digestion with Xanthomonas manihotis a(1,3)-fucosidase (E), or diges-
tion with X. manihotis a(1,2)-fucosidase (3). LacNAc and Lex standards
eluted at 7.8 and 13.2 min, respectively, under these conditions. B,
glycosidase analysis of H. pylori Fuc-T-generated product with LNT as
acceptor. Purified labeled product was analyzed by chromatography on
the Neutropak NH2 column using water/acetonitrile (30:70 by volume)
following no treatment (l), digestion with B. fragilis endo-b-galactosid-
ase (E), digestion with bovine testis b-galactosidase (3), or digestion
with bovine testis b-galactosidase and S. plicatus b-N-acetylhex-
osaminidase (f). In this system, LacNAc, Lex, and LNT standards
eluted at 4.3, 6.1, and 13.4 min, respectively. Endo-b-galactosidase
cleavage of LNT generated a product with a retention time of 9.3 min
(data not shown).
TABLE I
Fucosyltransferase activity of H. pylori fucT-containing plasmid
library clones
Cell extracts from E. coli XL-1 Blue containing library plasmids were
assayed for fucosyltransferase activity with LacNAc (5 mM) as a
substrate.
Clone Specific activity
pmol/mg/min
16I14 96
16E24 58
5F21 2.5
15M19 78
16G9 99
4F3 77
1C10 48
pUC18 0
No plasmid 0
TABLE II
Acceptor specificity of recombinant H. pylori FucT expressed in E. coli
Relative Fuc-T activity with a panel of oligosaccharide acceptors (5
mM) expressed as a percentage of activity with 5 mM LacNAc as sub-
strate (211 pmol/min/mg). A dash indicates a relative activity of , 2.5%.
Acceptor Relativeactivity
%
Galb134GlcNAc (1) 100
Galb133GlcNAc (2) —
Galb134(Fuca1–3)GlcNAc (3) —
Fuca133Galb1–4Glc (4) —
Fuca132Galb134Glc (5) —
NeuAca233Galb134GlcNAc (6) 44
NeuAca236Galb134GlcNAc (7) —
Manb134GlcNAc (8) 20
Galb134GlcNAcb133Galb134Glc (9) 171
Galb133GlcNAcb133Galb134Glc (10) 57
Fuca132Galb133GlcNAcb133Galb134Glc (11) 20
Galb133(Fuca134)GlcNAcb133Galb134Glc (12) 18
Galb134(Fuca133)GlcNAcb133Galb134Glc (13) 63
Fuca132Galb133(Fuca134)GlcNAcb133Galb134Glc (14) 17
Galb133(Fuca134)GlcNAcb133Galb134(Fuca133)Glc (15) —
Galb134GlcNAcb133Galb134(Fuca133)GlcNAc (16) 65
NeuAca233Galb133GlcNAcb133Galb134Glc (17) 39
Galb133(NeuAca236)GlcNAcb133Galb134Glc (18) —
NeuAca236Galb134GlcNAcb133Galb134Glc (19) 25
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tains no recognizable membrane insertion elements. Aligned
on the basis of the short, highly conserved region of homology
(Fig. 2), the bacterial enzyme appears to lack a region corre-
sponding to the transmembrane and stem domains of other
Fuc-Ts. Most of the “hypervariable region” previously impli-
cated in acceptor binding specificity in human Fuc-TIII and -V
(residues 34 to 161 in Fuc-TIII) (57) is also absent, suggesting
that the architecture of the H. pylori protein is substantially
different from the rest of the enzyme family. The alignment
also reveals that the C terminus of the bacterial sequence
extends for approximately 100 amino acids beyond that of the
other Fuc-Ts, half of this C-terminal extension being taken up
by a periodic 7-amino acid leucine zipper-like motif. The func-
tion of this region, which has no counterpart in mammalian or
avian Fuc-T sequences, is unknown. One possibility is that it
mediates homo- or heteromultimer formation through coiled-
coil type interactions, but at present the subunit structure of
the H. pylori protein is unknown and further work will be
necessary to establish the role of the zipper-like region.
Recombinant H. pylori Fuc-T has a strong preference for type
2 acceptors, and analysis of oligosaccharides generated by fu-
cosidase digestion of the product generated by this Fuc-T with
LacNAc indicates that H. pylori Fuc-T is indeed capable of
synthesizing the Lex epitope. Some type 1 structures are also
fucosylated, but our studies suggest that with these acceptors
fucose may be transferred predominantly to glucose rather
than GlcNAc, implying that the enzyme has little a(1,2)- or
a(1,4)-Fuc-T activity, as has been reported for human Fuc-TV
(51). Biosynthesis of the Ley epitope found on the surface of
many H. pylori isolates is therefore likely to involve a separate
a(1,2)-Fuc-T activity. Overall, the acceptor specificity of H.
pylori Fuc-T does not match that reported for any of the human
enzymes or indeed that of S. mansoni a(1,3)-Fuc-T (53). Like
the schistosome enzyme and human Fuc-Ts IV and VII, how-
ever, H. pylori Fuc-T shows only slight sensitivity to NEM
inhibition. Interestingly, 39-sialyl-LacNAc is an efficient accep-
tor (although 69-sialyl-LacNAc is not), implying that H. pylori
Fuc-T may be capable of synthesizing the sialyl-Lex (sLex)
structure which was recently detected in a small number of H.
pylori isolates by Wirth et al. (27). The absence of sLex from the
majority of H. pylori isolates may therefore reflect a lack of
sialyltransferase activity in these strains.
Mammalian a(1,3)-Fuc-Ts are a closely-related family of en-
zymes, making it difficult to identify residues of potential
structural and/or catalytic importance from sequence align-
ments. The recently cloned avian a(1,3)-Fuc-T, CFT-1 (45), also
shows a high level of sequence similarity to the corresponding
mammalian proteins, with 46.3% sequence identity to human
Fuc-TIV. This is not the case with the H. pylori enzyme, which
shows significant homology to the other a(1,3)-Fuc-Ts only in
one short region. A consensus motif derived from this local area
of homology (Fig. 2B) is unique to members of the a(1,3)-Fuc-T
family, including the H. pylori enzyme and an open reading
frame from a Caenorhabditis elegans cosmid4 (58). This highly
conserved a(1,3)-Fuc-T motif may be useful in identifying novel
a(1,3)-Fuc-T genes in genomic and expressed sequence tag
sequence data, since its appearance seems to be a reliable
predictor of membership of this enzyme family. It may also
provide a tool for cloning a(1,3)-Fuc-Ts in a manner similar to
the demonstrated utility of the L- and S-sialyl motifs in cloning
novel sialyltransferases (59).
The functional significance of the a(1,3)-Fuc-T motif is at
present unclear. Marked differences in acceptor preferences
among members of the a(1,3)-Fuc-T family would seem to ar-
gue against a role in acceptor binding. Human Fuc-TIV and
-VII for example both contain the a(1,3)-Fuc-T motif, but while
Fuc-TVII uses 2,3-sialylated acceptors almost exclusively, Fuc-
TIV strongly prefers neutral type 2 substrates (41) in in vitro
assays. The behavior of Fuc-TIV in vivo is apparently more
complex (60). The a(1,3)-Fuc-T motif lies outside sequence re-
gions implicated by efforts to define acceptor-discriminating
residues in a(1,3)-Fuc-Ts (51, 57, 61). Given that the enzymes
transfer fucose from a common sugar nucleotide donor, it seems
more likely that the a(1,3)-Fuc-T motif is involved in binding
GDP-fucose or Mn21. The motif lies some considerable distance
from a cysteine residue implicated in GDP-fucose protectable
inhibition by NEM (62), although it may be much closer in
space within the folded protein than the primary sequence
suggests. The corresponding position in the H. pylori Fuc-T is
occupied by tyrosine (Fig. 2A), in keeping with observations
that enzymes with Cys at this location are inhibited by NEM
while those with other amino acids (Fuc-TIV has Ser, Fuc-TVII
has Thr) are resistant to NEM inhibition (62).5 Interestingly,
the conserved motif contains a lysine residue (Fig. 2A), possibly
a candidate for the so far unidentified GDP-fucose-protected
lysine residue identified by pyridoxal phosphate labeling of a
human fucosyltransferase (63). Further work is clearly needed
to test these speculations, but in this respect the lack of overall
similarity between the H. pylori and mammalian transferase
sequences may be advantageous. The relatively small number
of conserved residues inside and outside the a(1,3)-Fuc-T motif
may provide a useful focus for mutagenesis experiments to
probe structural and mechanistic aspects of the a(1,3)-fucosyl-
transferases. The dissimilarity of H. pylori and human Fuc-T
enzymes would also seem to auger well for the design of selec-
tive inhibitors of the bacterial enzyme.
The H. pylori enzyme, which lacks a transmembrane domain
and is, presumably, nonglycosylated, is devoid of some of the
features which make eukaryotic Fuc-Ts difficult to work with.
The possibility of bacterial expression also makes this enzyme
a promising candidate for chemoenzymatic glycoconjugate syn-
thesis. The same features may simplify the task of structural
determination. Given the conserved motif, it seems reasonable
to assume that this enzyme shares at least some structural
features in common with its mammalian counterparts which
have so far resisted structural elucidation.
Mounting evidence appears to point to a role for Lewis anti-
gen mimicry in H. pylori pathogenesis. Identification and clon-
ing of a Fuc-T gene from this organism will allow us to probe
the biosynthesis of Lex by H. pylori in vivo via disruption of
fucT and may make it possible to test the role of Lex directly in
models of H. pylori pathogenesis.
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